UBS has successfully guided Haleon in its strategic acquisition of a 33% stake in Tianjin TSKF Pharmaceutical Co., Ltd., a deal valued at $636 million.
This move is a key part of Haleon’s strategy to penetrate the Chinese market, which is seeing a spike in demand for healthcare products due to its aging population and expanding middle class.
By partnering with Tianjin TSKF,
All the week’s industry events straight to your inbox.
By signing up you agree to our terms of use and privacy policy.
7 Bell Yard, London, England, WC2A 2JR
You will soon receive a Reset Password link
By signing up you agree to terms of use and privacy policy.
You must be logged in to post a comment.